Related references
Note: Only part of the references are listed.Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-α as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population
D. Castellano et al.
ANNALS OF ONCOLOGY (2009)
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
S. Novello et al.
BRITISH JOURNAL OF CANCER (2009)
Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer
Mark A. Socinski et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials
Katsuyuki Hotta et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248
Olga Potapova et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas
Y Shikada et al.
CANCER RESEARCH (2005)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Rhebbing up mTOR - New insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis
DJ Kwiatkowski
CANCER BIOLOGY & THERAPY (2003)
The biology of VEGF and its receptors
N Ferrara et al.
NATURE MEDICINE (2003)
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
AM O'Farrell et al.
BLOOD (2003)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small cell lung cancer
KJ O'Byrne et al.
BRITISH JOURNAL OF CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
